bazedoxifene has been researched along with Cancer of Ovary in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Heo, TH; Kim, HJ; Kim, LK; Park, HM; Park, SA | 1 |
| Lin, J; Reader, J; Roque, DM; Zhang, R | 1 |
| Lin, J; Wang, T; Zhang, R | 1 |
| Chines, AA; de Villiers, TJ; Hines, T; Levine, AB; Mirkin, S; Nardone, Fde C; Palacios, S; Williams, R | 1 |
| Gordon, IO; Greene, GL; Krausz, TN; Lee, W; Lengyel, E; Leonhardt, P; Mitra, AK; Mui, KL; Penicka, CV; Romero, IL; Zhao, Y | 1 |
| Bailey, S; Cukierski, MA; Earnhardt, JN; Komm, B; Minck, DR; Perry, R; Wright, DJ | 1 |
1 trial(s) available for bazedoxifene and Cancer of Ovary
| Article | Year |
|---|---|
Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study.
Topics: Aged; Bone Density Conservation Agents; Carcinoma, Ovarian Epithelial; Double-Blind Method; Endometrial Hyperplasia; Endometrial Neoplasms; Endometrium; Female; Humans; Incidence; Indoles; Middle Aged; Neoplasms, Glandular and Epithelial; Osteoporosis, Postmenopausal; Ovarian Neoplasms; Postmenopause; Selective Estrogen Receptor Modulators; Spinal Fractures; Ultrasonography; Vaginitis | 2013 |
5 other study(ies) available for bazedoxifene and Cancer of Ovary
| Article | Year |
|---|---|
Inhibition of GP130/STAT3 and EMT by combined bazedoxifene and paclitaxel treatment in ovarian cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cytokine Receptor gp130; Drug Therapy, Combination; Epithelial-Mesenchymal Transition; Female; Glycoproteins; Humans; Indoles; Mice; Mice, Inbred BALB C; Ovarian Neoplasms; Paclitaxel; Selective Estrogen Receptor Modulators; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2022 |
Combined inhibition of IL‑6 and IL‑8 pathways suppresses ovarian cancer cell viability and migration and tumor growth.
Topics: Animals; Benzamides; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclobutanes; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; Indoles; Interleukin-6; Interleukin-8; Mice; Ovarian Neoplasms; Selective Estrogen Receptor Modulators | 2022 |
Synergistic Effect of Bazedoxifene and PARP Inhibitor in the Treatment of Ovarian Cancer Regardless of BRCA Mutation.
Topics: BRCA1 Protein; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Indoles; Interleukin-6; Mutation; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Time Factors | 2021 |
The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis.
Topics: Animals; Cell Growth Processes; Cell Line, Tumor; Cell Transformation, Neoplastic; Disease Models, Animal; Drug Interactions; Estradiol; Estrogen Antagonists; Female; Genetic Predisposition to Disease; Indoles; Mice; Mice, Transgenic; Neoplasm Invasiveness; Ovarian Neoplasms; Ovary; Selective Estrogen Receptor Modulators | 2012 |
Carcinogenicity and hormone studies with the tissue-selective estrogen receptor modulator bazadoxifene.
Topics: Animals; Body Weight; Carcinogenicity Tests; Carcinogens; Cysts; Estradiol; Estrogens; Female; Food Contamination; Haplorhini; Indoles; Luteinizing Hormone; Male; Ovarian Neoplasms; Pituitary Gland; Pituitary Neoplasms; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Selective Estrogen Receptor Modulators | 2013 |